These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. Alvarez-Uria G; Ratcliffe L; Vilar J HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695 [TBL] [Abstract][Full Text] [Related]
7. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy. Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858 [TBL] [Abstract][Full Text] [Related]
8. Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia. Childs K; Joshi D; Byrne R; Bruce M; Carey I; Agarwal K; Taylor C AIDS; 2013 Jun; 27(9):1443-8. PubMed ID: 23435302 [TBL] [Abstract][Full Text] [Related]
9. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735 [TBL] [Abstract][Full Text] [Related]
10. New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings. Dunn D; Price H; Vudriko T; Kityo C; Musoro G; Hakim J; Gilks C; Kaleebu P; Pillay D; Gilson R; J Acquir Immune Defic Syndr; 2021 Jan; 86(1):98-103. PubMed ID: 33306565 [TBL] [Abstract][Full Text] [Related]
12. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313 [TBL] [Abstract][Full Text] [Related]
13. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235 [TBL] [Abstract][Full Text] [Related]
14. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Kitrinos KM; Corsa A; Liu Y; Flaherty J; Snow-Lampart A; Marcellin P; Borroto-Esoda K; Miller MD Hepatology; 2014 Feb; 59(2):434-42. PubMed ID: 23939953 [TBL] [Abstract][Full Text] [Related]
15. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552 [TBL] [Abstract][Full Text] [Related]
16. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608 [TBL] [Abstract][Full Text] [Related]
17. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of chronic hepatitis B in HIV co-infected patients]. Massard J; Benhamou Y Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt 2):S20-4. PubMed ID: 18662606 [TBL] [Abstract][Full Text] [Related]
19. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients. Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040 [TBL] [Abstract][Full Text] [Related]
20. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi. Galluzzo C; Liotta G; Andreotti M; Luhanga R; Jere H; Mancinelli S; Maulidi M; Sagno JB; Pirillo M; Erba F; Amici R; Ceffa S; Marazzi MC; Vella S; Palombi L; Giuliano M J Med Virol; 2012 Oct; 84(10):1553-7. PubMed ID: 22930502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]